World's first once-weekly insulin launched in India: Check prices

World's first once-weekly insulin launched in India: Check prices

Danish pharmaceutical company Novo Nordisk has launched Awiqli, the world's first once-weekly basal insulin for adults with Type 1 and Type 2 diabetes.

The launch marks a major shift in diabetes management as it reduces the number of insulin injections from 365 a year to just one every week.

Awiqli is expected to address one of the biggest barriers to insulin adoption in India, the fear of daily injections.

Addressing India's diabetes burden

India is home to over 101 million people with diabetes and another 136 million with prediabetes.

The country also has over nine lakh people suffering from Type 1 diabetes, an autoimmune condition that requires insulin therapy for management.

About 10% of those with Type 2 diabetes also require insulin therapy.

Awiqli could help improve treatment adherence and encourage earlier insulin initiation among patients who are reluctant to start therapy due to fears of daily injections.